ACIP Anthrax Work Group Members

ACIP Members: David Stephens, Chair; Robert L. Atmar

Ex Officio Members: Judy Hewitt (NIH); Eric Espeland (BARDA); Alexandra Worobec (FDA); Eric Deussing (DOD); Kim Taylor (NIH); Chia-Wei Tsai (BARDA); Julianne Clifford (FDA)

Liaison Representatives: Richard Beigi (ACOG); Kathleen Neuzil (IDSA); James Campbell (AAP); Matthew Zahn (NACCHO)

Invited Consultants: Wendy Keitel; Arthur Friedlander; Phillip Pittman; Andy Pavia

CDC: William Bower, Lead
Terms of Reference

Review new data on Anthrax Vaccine Adsorbed (AVA) including:

- New safety studies
- Immunogenicity, reactogenicity and logistical considerations for administering AVA via the subcutaneous versus the intramuscular route for administration as Post Exposure Prophylaxis (PEP)
- AVA plus CPG 7909 adjuvant data use as post-exposure prophylaxis
- Efficacy and immunogenicity data on dose-sparing strategies for PEP during a mass casualty incident when AVA is a limited resource
- Data on reduced booster schedule for pre-exposure prophylaxis
- Advise on the use of AVA and antitoxin for PEP when no effective antimicrobials are available or have an absolute contraindication
Today’s session

- Discuss preparedness/operational concerns during an anthrax mass casualty event

- Review new safety data
  - Adverse events related to IM vs. SC route of administration

- Review data on immunogenicity for IM versus SC route of administration

- Summary